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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.021The two major melanoma histologic subtypes, superﬁcial spreading and nodular melanomas, differ in
their speed of dermal invasion but converge biologically once they invade and metastasize. Herein, we
tested the hypothesis that distinct molecular alterations arising in primary melanoma cells might persist
as these tumors progress to invasion and metastasis. Ribosomal protein S6 kinase, 90 kDa, polypeptide 1
(RSK1; ofﬁcial name RPS6KA1) was signiﬁcantly hyperactivated in human melanoma lines and metastatic
tissues derived from nodular compared with superﬁcial spreading melanoma. RSK1 was constitutively
phosphorylated at Ser-380 in nodular but not superﬁcial spreading melanoma and did not directly
correlate with BRAF or MEK activation. Nodular melanoma cells were more sensitive to RSK1 inhibition
using siRNA and the pharmacological inhibitor BI-D1870 compared with superﬁcial spreading cells. Gene
expression microarray analyses revealed that RSK1 orchestrated a program of gene expression that
promoted cell motility and invasion. Differential overexpression of the prometastatic matrix metal-
loproteinase 8 and tissue inhibitor of metalloproteinases 1 in metastatic nodular compared with meta-
static superﬁcial spreading melanoma was observed. Finally, using an in vivo zebraﬁsh model, constitutive
RSK1 activation increased melanoma invasion. Together, these data reveal a novel role for activated RSK1
in the progression of nodular melanoma and suggest that melanoma originating from different histologic
subtypes may be biologically distinct and that these differences are maintained as the tumors invade and
metastasize. (Am J Pathol 2015, 185: 704e716; http://dx.doi.org/10.1016/j.ajpath.2014.11.021)Supported by the NIH Cancer Center Support Grant to the New York
University Perlmutter Cancer Center (P30 CA016087), The Chemotherapy
Foundation grant 15-C0300-82115 (I.O.), the American Skin Association
grant 12-00009 (J.A.F.), The Skin Cancer Foundation (J.A.F.), and the
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Disclosures: None declared.Superﬁcial spreading melanoma (SSM) and nodular mela-
noma (NM) represent the two most common primary mel-
anoma histologic subtypes, accounting for 70% and 15% to
20% of cases, respectively.1,2 SSM is characterized by a
radial growth phase (RGP) consisting of an intraepidermal
component. Whereas SSM can proceed from a RGP to a
vertical growth phase (VGP) and ﬁnally to distant metas-
tases, NM grows rapidly in a vertical manner (VGP), with
no horizontal growth phase.3
To date, the prognostic and therapeutic impact of mela-
noma histologic subtypes has been relatively limited. The
American Joint Committee on Cancer staging system uses
tumor thickness, ulceration, mitotic index, and lymph node
status, but not histologic subtype, in the recurrence/metas-
tasis risk assessment of patients with primary localized
melanoma.4 This is, in part, due to the current linear modelstigative Pathology.
.of melanoma progression, which dictates that melanoma
begins with the transformation of epidermal melanocytes
and an initial RGP, followed by a subsequent transition to a
VGP and distant metastasis.5e7 Hence, it is generally
accepted that the speed of dermal invasion is the only aspect
that differentiates the NM and SSM subtypes.
Recent discoveries in other solid tumor types emphasize
the potential role of histology-driven molecular character-
ization to assist in the diagnosis and treatment of cancer.8e11
RSK1 Hyperactivation in Nodular MelanomaIndeed, the utility of histologic classiﬁcation in melanoma
has been demonstrated with acral lentiginous melanoma,
which composes approximately 10% of primary melanomas.
The prevalence of molecular alterations in the c-KIT onco-
gene in this histologic melanoma subtype has deﬁned acral
lentiginous melanoma as a distinct and useful subclassiﬁ-
cation of melanoma, and a phase 2 trial of the c-KIT inhibitor
imatinib validated the rationale of subtype-speciﬁc therapy
for this group of melanoma patients.12 In contrast, the clinical
relevance of the SSM and NM subtypes has been largely
overlooked.
Recent reports by our groups and others suggest that pri-
mary SSM and NMmight be distinct biological entities.13e19
Unbiased, high-throughput genetic techniques, such as
comparative genomic hybridization, single nucleotide poly-
morphism arrays, and microarrays, have revealed the pres-
ence of recurrent SSM-speciﬁc deletions that are present or
even ampliﬁed in NM and, thus, cannot be reconciled with
the linear progression model, even when epigenetic modiﬁ-
cations are taken into account. Similarly, signiﬁcant alter-
ations in mRNA and miRNA gene expression are observed
when comparing SSM with nevi and NM, and these alter-
ations cannot be explained by the existing stepwise (linear)
model.16,17 Together, these ﬁndings suggest that distinct
molecular alterations between SSM and NM might underlie
the biological differences between these subtypes. However,
it is unclear whether differences that exist between primary
SSM and NM are retained during progression to invasion and
metastasis.
Herein, we tested the hypothesis that subtype-speciﬁc dif-
ferences between SSMandNMpersist throughout progression
of primary melanoma to metastatic disease. We used a com-
bination of human melanoma cell lines representing SSM and
NM, human tissues from metastatic SSM and NM, and a
zebraﬁsh model of melanoma to demonstrate the role of pro-
tein S6 kinase, 90 kDa, polypeptide 1 (RSK1; ofﬁcial name
RPS6KA1) in melanoma invasion in vitro and in vivo. These
data suggest that metastatic melanoma originating from
different histologic subtypes might be biologically distinct and
reveal differences that are maintained from the primary tumor
to metastatic disease.
Materials and Methods
Cell Culture
Melanoma cell lines representing RGP (WM 35, WM 1552c,
WM 1575, and WM 3211) and VGP (WM 98.1, WM 115,
WM 278, WM 793c, WM 853.2, WM 902, WM 983e, WM
1361, WM 1366, and WM 3248) melanoma were purchased
commercially from The Wistar Institute (Philadelphia, PA).
Primary cell lines were cultured in MCDB153/L15 medium
(4/1 v/v) supplemented with 2% fetal bovine serum, 5 mg/mL
insulin, 15 mg/mL bovine pituitary extract, 1.68 mmol/L
calcium chloride, 5 ng/mL epidermal growth factor, and 1%
penicillin/streptomycin. Human epidermal melanocytes wereThe American Journal of Pathology - ajp.amjpathol.orgcultured in DermaLife M melanocyte culture medium
(Lifeline Cell Technology, Frederick, MD).
Western Blot Analysis and Antibodies
Cells and human tissues were harvested in extraction buffer,
and Western blot analysis was performed as previously
described.13 Phospho-RSK (p-RSK) (Ser-363; #9344),
phospho-RSK (Ser-380; #9335), total RSK (#9335), RSK1
(#8408), and RSK2 (#9340) were purchased from Cell
Signaling Technology Inc. (Beverly, MA). Anti-Ran (sc-1156)
antibodywas purchased fromSanta CruzBiotechnology (Santa
Cruz, CA).
Cell Proliferation Assay
Speciﬁed cell lines were seeded at 5 to 10  103 cells per
well in a 96-well plate in complete medium. The next day,
cells were treated with equal amounts of dimethyl sulf-
oxide (DMSO) or the indicated concentration of BI-D1870
(purchased from the Division of Signal Transduction
Therapy, University of Dundee, Scotland, UK) and were
cultured for 72 hours. Cells were ﬁxed with cold 1%
glutaraldehyde, washed with phosphate-buffered saline,
and stained with 0.1% crystal violet and 20% methanol.
Cells were destained with 15% acetic acid, and absorbance
was read at 595 nm using a FlexStation 3 benchtop multi-
mode microplate reader (Molecular Devices, Sunnyvale,
CA). Half maximal inhibitory concentrations were calcu-
lated using GraphPad Prism software version 6 (GraphPad
Software Inc., La Jolla, CA).
RNA Extraction and Quantitative RT-PCR
RNA extraction and quantitative RT-PCR were used to
verify siRNA target knockdown and to validate the mRNA
array. Total RNA was isolated from cells or tumors using a
QIAshredder and RNeasy mini kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. For
mRNA detection, 1 mg of DNAse-treated RNA (DNA-free
kit; Invitrogen, Carlsbad, CA) was reverse transcribed using
a RETROscript kit (Invitrogen), and quantitative RT-PCRs
were performed using gene-speciﬁc primers and a MyiQ
Real-time PCR system (Bio-Rad Laboratories, Hercules,
CA). Quantitative normalization was performed on the
expression of glyceraldehyde-3-phosphate dehydrogenase.
The relative expression levels between samples were
calculated using the 2DDCT method, with a control sample
as the reference point.14 Primer sequences are summarized
in Table 1.
Serum Starvation
Cells (4  105) of speciﬁed cell lines were seeded in three
6-cm plates. The next day, growth medium in two-thirds of
the plates was replaced with medium containing MCDB153/705
Table 1 Primers Used for Quantitative RT-PCR
Gene Forward primers Reverse primers
RPS6KA1 50-TGAAGGTGCTGAAGAAGGCA-30 50-CAGCTTCACCACGAATGGGT-30
RPS6KA3 50-AACCTATGGGAGAGGAGGAGA-30 50-AGGATCTGCCTTTTCATGTCC-30
GAPDH 50-GAGCCACATCGCTCAGACAC-30 50-CATGTAGTTGAGGTCAATGAAGG-30
MMP2 50-AAGCCACTGACCAGCCTGGGA-30 50-AGGCATCTGCGATGAGCTTGGG-30
CCL2 50-AGCAAGTGTCCCAAAGAAGCTGTG-30 50-AGCTGCAGATTCTTGGGTTGTGGA-30
ATF1 50-ACGGCGCCCATCTTACAGAAAAA-30 50-ACTGTAAGGCTCCATTTGGGGCAA-30
TIMP3 50-GGTCTACACCATCAAGCAGAT-30 50-AGCCCCGTGTACATCTTGCCATCATA-30
IL8 50-TTTCAGAGACAGCAGAGCACACAAGC-30 50-CACCTTCACACAGAGCTGCAGAAA-30
CXCL1 50-TATTTCTGAGGAGCCTGCAACATGCC-30 50-GCACATACATTCCCCTGCCTTCACAAT-30
Salhi et alL15 medium (4/1 v/v), 1% primary melanoma cell medium,
and 1% penicillin/streptomycin. After 24 hours, one serum-
starved plate was stimulated for 10 minutes with complete
primary melanoma cell medium. Plates were then trypsinized,
washed with phosphate-buffered saline, and harvested for
Western blot analysis.
Transfection of siRNAs
Cells were plated in 12-well plates at 30% to 50% con-
ﬂuency and transfected 24 hours later with 20 pmol/L
siRNA using Lipofectamine 2000 reagent (Invitrogen
Life Technologies, Grand Island, NY), according to the
manufacturer’s instructions. RSK1 (#S12275), RSK2
(#S12279), and negative control (#4390843) siRNA were
purchased from Invitrogen Life Technologies. mRNA
knockdown was quantiﬁed 48 hours later by quantitative
RT-PCR.
Gene Expression Array
For expression proﬁling, we used the Affymetrix Gen-
eChip system (Affymetrix Inc., Santa Clara, CA). The
RNA quality and quantity were determined using a 2100
Bioanalyzer system (Agilent Technologies Inc., Santa
Clara, CA) and a NanoDrop ND-1000 spectrophotometer
(Thermo Scientiﬁc, Wilmington, DE). Total RNA (100
ng) extracted from WM 278 or WM 3248 cells treated for
24 or 48 hours with equal amounts of 5 mmol/L BI-D1870
or DMSO in duplicate were used to prepare cRNA
following the 30 IVT express kit (Affymetrix Inc.) labeling
protocol and standardized array processing procedures
recommended by Affymetrix Inc., including hybridiza-
tion, ﬂuidics processing, and scanning of the Affymetrix
HG-U133 plus 2.0 arrays (Affymetrix Inc.). The raw data
(Affymetrix CEL ﬁles) were normalized using the Robust
Multichip Average algorithm in the GeneSpring GX
software version 11 (Agilent Technologies Inc.).15
Differentially expressed genes between BI-D1870 cells
and DMSO-treated cells were determined by Pavlidis
Template Matching at P < 0.005, thresholded for fold
change of 33%.12 The resulting genes were used for
interpretation and validation analyses.706Statistical Analysis
Unless otherwise noted, data are presented as means  SEM,
and the two-tailed Student’s t-test was used for comparison,
with P < 0.05, P < 0.01, and P < 0.001 considered to be
statistically signiﬁcant.
Protein Pathway Array
A protein pathway array was performed as previously
described.20e22 RGP (WM 35, WM 1552c, and WM 1575)
and VGP (WM 98.1, WM 983e, and WM 3248) cells were
seeded at 1.0  106 cells per 10-cm dish and grown to 80%
conﬂuence before harvesting. Total proteins were extracted
from the cells using 1 cell lysis buffer (Cell Signaling
Technology Inc., Danvers, MA) in the presence of
1 protease inhibitor and 1 phosphatase inhibitor cock-
tails (Roche Applied Science, Indianapolis, IN). Protein
lysate (300 mg) was loaded in 1 well across the entire width
of a 10% SDS-PAGE polyacrylamide gel, separated by
electrophoresis, and blotted with 141 protein-speciﬁc or
phosphorylation siteespeciﬁc antibodies as described else-
where.20e22 All the antibodies were validated independently
before inclusion in the pathway array. For protein pathway
array data analysis, the signal intensity of each protein band
was determined by densitometric scanning (Quantity One
software package; Bio-Rad Laboratories). The background
was locally subtracted from the raw protein signal, and the
background-subtracted intensity was normalized by a
global median subtraction normalization method to reduce
the variations arising from different runs (such as trans-
ferring and blotting efﬁciency, total protein loading
amount, and exposure density). The normalized data were
used in subsequent statistical analyses. Differentially
expressed proteins were identiﬁed by Pavlidis Template
Matching at P < 0.05.23
Cell Migration and Invasion Assays
Cells (1  106) were seeded in 10-cm dishes and were
treated the next day for 24 hours with equal amounts of
either DMSO or 5 mmol/L of BI-D1870. Cells (5  104 for
migration assay or 9  104 for invasion assay) in serum-freeajp.amjpathol.org - The American Journal of Pathology
RSK1 Hyperactivation in Nodular Melanomamedium containing equal amounts of DMSO or 5 mmol/L
BI-D1870 were seeded in triplicate into the upper chamber
of a porous 8-mm polyethylene terephthalate insert (BD
Biosciences, Franklin Lakes, NJ) in a 24-well plate con-
taining complete medium (chemoattractant). For invasion
assays, the insert was coated with Matrigel (BD Bio-
sciences). After 6 hours for migration assay or 20 hours for
invasion assay, cells remaining in the upper chamber were
carefully removed using a cotton swab. Cells adhering to the
bottom of the ﬁlter were ﬁxed with cold 1% glutaraldehyde
and stained with 0.1% crystal violet and 20% methanol.
Five high-power ﬁelds were photographed for each insert
using an Axiovert 10 inverted microscope (Carl Zeiss,
Oberkochen, Germany) and were counted.
Matrix Metalloproteinase Antibody Array
Metastatic samples from SSM and NM patients (n Z 4 for
each group) were analyzed for the expression of matrix
metalloproteinases (MMPs) and tissue inhibitor of metal-
loproteinases (TIMPs) using a human MMP antibody array I
(RayBiotech Inc., Norcross GA), according to the manu-
facturer’s instructions. Total protein was extracted using
lysis buffer and was quantiﬁed using the BCA protein assay
(Thermo Scientiﬁc). Samples were incubated on the array
membranes for 2 hours before washing the membranes and
incubation with biotin-conjugated primary antibodies. The
expression of MMPs and TIMPs was determined using
chemiluminescence imaging and was quantiﬁed as pixel
values. Mean values for duplicate samples were calculated
and normalized using the positive controls.
Immunohistochemical Analysis
Immunohistochemical analysis was performed using
formalin-ﬁxed, parafﬁn-embedded metastatic samples from
SSM and NM patients (n Z 9 and n Z 10, respectively).
Tissues were evaluated for MMP-8 expression using an
MMP-8especiﬁc rabbit polyclonal antibody (catalog
#ab78423, diluted 1:500; Abcam Inc., Cambridge, MA). An
attending pathologist [Farbod Darvishian (New York, NY)]
scored the expression of MMP-8 in each sample on a scale
from 0 to 2.
Zebraﬁsh Studies
MiniCoopR vectors were created using Gateway recombina-
tion (Invitrogen) as previously described.24 A constitutively
active human RSK1 was cloned by adding an N-terminal
myristoylation sequence (Myr-RSK1).25 For embryo assays,
we performed microinjection of zebraﬁsh embryos from
an incross of nacre [nacre has a missense mutation in mitf
(C417T/C417T) and results in loss of function], roy, and
p53(M214K/M214K). Individual embryos were photo-
graphed using a Zeiss V8 stereoscope (Carl Zeiss) under
transmitted light. For adult melanoma assays, we performedThe American Journal of Pathology - ajp.amjpathol.orgmicroinjection of zebraﬁsh embryos from an incross of
Tg[mitfa:BRAF(V600E);p53(M214K/M214K);nacre]. We
raised melanocyte-rescued animals to adulthood and per-
formed weekly observations for melanoma onset as previ-
ously described.26
Results
p-RSK1 Is Differentially Expressed in Human Melanoma
Lines and Tissues Derived from Different Histologic
Subtypes
To identify signaling pathways that were differentially
expressed or activated between RGP and VGP melanoma,
we used a protein pathway array with duplicate protein
samples using 141 protein- and phospho-speciﬁc antibodies
(Supplemental Table S1) with protein extracts from three
RGP and three VGP melanoma cell lines (RGP: WM 35,
WM 1552c, and WM 1575; VGP: WM 983e, WM 98.1,
and WM 3248), and we used the Pavlidis Template
Matching algorithm23 (P < 0.05) in TIGR MultiExperiment
Viewer (Dana-Farber Cancer Institute, Boston, MA) to
identify 18 proteins or phospho-proteins (12.8%) that were
differentially expressed between the two groups (Figure 1A
and Supplemental Table S2). Of particular interest, the
phosphorylated form of p90 ribosomal S6 kinase (RSK)
was overexpressed in two independent experiments
(PZ 0.02 and PZ 0.01) in VGP cell lines compared with
RGP-derived cells. The vertebrate 90-kDa ribosomal S6
kinase (RSK1) family consists of four isoforms in humans,
RSK1 to RSK4, which share 73% to 80% sequence ho-
mology at the amino acid level and are located downstream
of extracellular signal-regulated (ERK) 1/2 in the mitogen-
activated protein kinase (MAPK)/ERK signaling pathway.27
In addition to it belonging to the MAPK/ERK pathway, we
chose to focus on RSK1 in this study for several reasons: we
found p-RSK1 to be signiﬁcantly differentially expressed
between the two types of cell lines in two independent runs;
deregulated RSK1 activity has been previously associated
with other types of cancer,28,29 including melanoma.30 The
present data extend these observations by suggesting that
there may be preferential up-regulation of RSK1 activity in
VGP melanoma.
To establish whether RSK1 activation was correlated with
the NM histologic subtype, we ﬁrst investigated whether
there was constitutive activation of RSK1 (p-RSK1) in VGP
(NM-derived) melanoma cells. We considered an exclusively
RGP cell line to be of SSM origin as, by deﬁnition, NM
cannot have an RGP component. In contrast, VGP melanoma
may be derived from NM or from SSM that progressed from
RGP to acquire a VGP. Therefore, we equated VGP cell lines
as NM only when there was published evidence stating that
the tumor of origin was from the NM histologic subtype. We
tested whether mitogenic (growth factor) stimulation was
required to induce RSK1 phosphorylation in SSM versus NM
cells. We, therefore, compared two primary NM cell lines707
Figure 1 Differential expression/phosphorylation of tumorigenic pathways in radial (RGP) versus vertical (VGP) growth phase melanoma. A: Heat map
generated from a protein pathway array demonstrating differential expression/phosphorylation of tumorigenic proteins in three RGP (WM 35, WM 1552c, and
WM 1575) and three VGP (WM 98.1, WM 983e, and WM 3248) cell lines in duplicate (P < 0.05). Blue bars indicate proteins or phospho-proteins that were
down-regulated; red bars, proteins or phospho-proteins that were up-regulated. B: Protein S6 kinase, 90 kDa, polypeptide 1 (RSK1) phosphorylation was serum
dependent in superﬁcial spreading melanoma (SSM) cells (WM 35 and WM 1552), whereas RSK1 was constitutively phosphorylated in a serum-independent
manner in nodular melanoma (NM) cells (WM 3248 and WM 278). C: Phospho-RSK1 (p-RSK1) up-regulation cannot be exclusively explained by BRAF muta-
tion status or extracellular signal-regulated (ERK) activation. Western blot analysis on an expanded panel of 14 primary melanoma cell lines. Boxes highlight
cell lines in which phospho-ERK (p-ERK) and p-RSK levels did not directly correlate. D: p-RSK1 protein expression in human metastatic melanoma tissues by
Western blot analysis in two melanocyte cell lines (HEM-377 and HEM-475), one human normal skin sample (NS), four human SSM metastatic tissues, and four
human NM metastatic tissues. RSK was overexpressed and hyperphosphorylated at Ser-363 and Ser-380 in metastatic tissues, whereas RSK1 phosphorylation
was absent in melanocytes and normal skin. Phospho-liver kinase B1 (p-LKB1), a known downstream effector of RSK1, was used as a control for p-RSK1
activation. Data are given as means  SEM. MT, mutation; S.S., steady state; Starv., serum starved for 24 hours; Stim., serum starved for 24 hours, then
stimulated for 10 minutes with serum; WT, wild type.
Salhi et al(WM 278 and WM 3248) with two primary SSM cell lines
(WM 35 and WM 1552c).
After 24 hours of serum starvation, we observed that
RSK1 phosphorylation at Ser-380 was suppressed in SSM
melanoma cell lines (WM 35 and WM 1552c) and then
induced in these cells after 10 minutes of serum stimu-
lation (Figure 1B). One SSM cell line (WM 1552)
showed a higher level of baseline p-RSK1. However, we
observed complete suppression of p-RSK1 on serum
starvation of this cell line, suggesting that the SSM sub-
type may not be reliant on constitutively active RSK1. In
contrast, NM cells (WM 278 and WM 3248) maintained
RSK1 phosphorylation at Ser-380 after 24 hours of serum
starvation and on serum stimulation (Figure 1B), sug-
gesting that RSK1 may be constitutively phosphorylated
at Ser-380 in NM irrespective of the presence of mito-
genic stimuli.
Because RSK1 is an established downstream effector of
the MAPK pathway,31,32 we reasoned that RSK1 hyper-
activation might be due to activating BRAF mutations, the
most common somatic MAPK pathway alteration in mel-
anoma.33e35 We investigated this possibility by evaluating708the relationship between p-RSK1 levels and activation of
the MAPK pathway in an expanded panel of 14 melanoma
cell lines (12 BRAF mutants and two BRAF wild types).
Whereas four cell lines had higher expression of p-ERK
than p-RSK1 (WM 278, WM 793, WM 853, and WM
902) by Western blot analysis, ﬁve cell lines showed low
or no detectable expression of p-ERK (WM 115, WM
983, WM 1366, WM 1361, and WM 3248). For the latter
cell lines, we observed high p-RSK1 expression despite
the absence of p-ERK, suggesting that in some tumors
RSK1 activation might occur independently of upstream
MAPK activation or BRAF mutation (Figure 1C and
Supplemental Figure S1). Although the four cell lines shown
in Figure 1B all harbored a BRAF mutation, we observed a
distinct p-RSK1 response to starvation, suggesting the inde-
pendency of this event from MAPK activation. Together,
these data suggest that RSK1 activation in melanoma cells
can occur independently of upstream MAPK pathway
activation.
To conﬁrm that RSK1 is constitutively activated in
human melanoma in a subtype-speciﬁc manner, we used
Western blot analysis to analyze p-RSK1 expression inajp.amjpathol.org - The American Journal of Pathology
Figure 2 Genetic or pharmacological inhibition of protein S6 kinase, 90 kDa, polypeptide 1 (RSK1) inhibits nodular melanoma (NM) but not superﬁcial
spreading melanoma (SSM) cell proliferation. A: Western blot analysis showing RSK1 levels after transfection with nontargeting (N.T.), RSK1-targeting, or
RSK2-targeting siRNA in WM 1552 melanoma cells (SSM). B: Crystal violet proliferation assay of SSM cells 48 hours after transient transfection with RSK1 or
RSK2 siRNA or 72 hours after treatment with escalating doses of the RSK inhibitor BI-D1870. Data were normalized by setting N.T. siRNA-transfected or
dimethyl sulfoxide (DMSO)etreated cells to 100%. C: Same as in A but using WM 3248 melanoma cells (NM). D: Same as in B but using NM cell lines. Data are
given as means  SEM. **P < 0.01, ***P < 0.001 compared with N.T. siRNA-transfected cells.
RSK1 Hyperactivation in Nodular Melanomatissues from the New York University melanoma clinico-
pathologic biospecimen database.36 We observed little or no
detectable expression of p-RSK1 in melanocytes, normal
skin, or metastatic samples from SSM patients, whereas
p-RSK1 was strongly expressed in human metastatic tissues
originating from NM (Figure 1D). In one metastatic sample
originating from primary NM, we observed a second, upper
p-RSK1 band that we hypothesize might relate to multiple
phosphorylation states of RSK1 in this specimen. Indeed,
besides its ERK1/2 binding domain (Ser-363), RSK1 con-
tains several domains involved in kinase activation (Ser-221
and Ser-732) or autophosphorylation (Ser-380) that are
responsible for its complete activation. To further conﬁrm the
overexpression of p-RSK1 in the metastatic NM subtype, we
also assessed the activation status of the protein kinase liver
kinase B1 (also known as serine/threonine kinase 11), a
known RSK1 substrate,37 in metastatic melanoma tissues and
observed elevated phosphorylation of liver kinase B1 at Ser-
431 speciﬁcally in metastatic tissues that originated from NM
(Figure 1D). Taken together, these ﬁndings in melanoma cell
lines and patient tissues indicate that RSK1 is preferentiallyThe American Journal of Pathology - ajp.amjpathol.orgactivated in human primary and metastatic NM compared
with SSM.RSK1 Inhibition Decreases Cell Proliferation in NM but
Not SSM Cell Lines
RSK1 and RSK2 have been previously implicated in can-
cer,28,29,38 including melanoma,30 where they regulate nuclear
signaling, cell-cycle progression, and cell proliferation, sur-
vival, and migration, as well as nuclear signaling and protein
synthesis. Therefore, we sought to determine the relative
dependence of SSM and NM melanoma cell lines on RSK1
and RSK2.We used two SSM cell lines and two NM cell lines
that were either transfected with RSK1- or RSK2-targeting
siRNA or, alternatively, treated with a potent small-molecule
RSK inhibitor, BI-D1870, that is speciﬁc for all four RSK
isoforms and acts by reversibly competing with ATP binding
to the N-terminal kinase domain ATP-interacting sequence.39
Notably, when tested against a panel of >50 other kinases,
BI-D1870 did not block their activity even at concentrations709
Figure 3 p90 ribosomal S6 kinase (RSK) inhibition decreases nodular melanoma (NM) cell migration and invasion. A: WM 278 and WM 3248 cells treated
with equal amounts of dimethyl sulfoxide (DMSO) or 5 mmol/L BI-D1870 migrated through 8-mm migration chambers for 6 hours and then were ﬁxed and
stained with crystal violet. Five high-power ﬁelds from each chamber were photographed, and cells were then counted. Images shown are representative of one
high-power ﬁeld from each condition. B: Same as A but chamber coated with Matrigel and cells allowed to invade for 20 hours. For A and B, data were
normalized by setting DMSO-treated cells to 100%. C: Same as B but using siRNA against RSK1. Data are given as means  SEM. ***P < 0.001 compared with
DMSO-treated cells (A and B) or with scrambled siRNAetreated cells (C).
Salhi et al>100-fold higher than that needed to block RSK
phosphorylation.39
RNA interference knockdown of RSK1 in SSM cells
(WM 1552 and WM 3211) (Figure 2A) induced a modest
decrease in cell proliferation compared with nontargeting
siRNA (Figure 2B), whereas transfection of NM cell lines
with RSK2-targeting siRNA (Figure 2A) did not produce
a change in cell proliferation (Figure 2B). Consistent with
these ﬁndings, treating SSM cells with BI-D1870 for 72
hours induced a minimal decrease in proliferation (Figure 2B).
In contrast, RNA interferenceemediated knockdown of RSK1
in NM cell lines (WM 278 and WM 3248) (Figure 2C)
resulted in a signiﬁcant reduction in cell proliferation
(51.8% reduction for WM 278 cells and 48.2% reduction
for WM 3248 cells; P < 0.001) (Figure 2D). To conﬁrm
the effects of RSK1 knockdown, we tested two different
siRNA molecules that were designed to speciﬁcally target
RSK1 (Supplemental Figure S2). We selected the one
displaying the most signiﬁcant level of suppression
(siRNA #1). By comparison, RSK2 knockdown (Figure 2C)
induced a modest, nonsigniﬁcant reduction in WM 278
proliferation and a 19.0% increase (P < 0.05) in WM
3248 proliferation (Figure 2D). Treating NM cells with
the small-molecule RSK inhibitor BI-D1870 for 72 hours
induced a marked dose-dependent reduction in cell pro-
liferation, with half maximal inhibitory concentrations of 9.5
and 3.1 mmol/L in WM 278 and WM 3248 cells, respectively710(Figure 2D). To conﬁrm this result, we treated an additional
NM melanoma cell line with BI-D1870 and observed a
similar dose-dependent reduction in cell proliferation
(WM 1366; half maximal inhibitory concentration, 2.6
mmol/L) (Supplemental Figure S3). The RNA interference
data are consistent with the BI-D1870 inhibitor data and
demonstrate that pharmacological or genetic inhibition of
RSK1 but not RSK2 can inhibit the growth of NM cells,
supporting the postulate that NM cells depend on acti-
vated RSK1 to sustain their proliferation.
RSK1 Activation Promotes Migration and Invasion of
NM-Derived Cells
Elevated cell migration and invasion are hallmarks of
melanoma, and these processes support and promote met-
astatic progression of the disease and, ultimately, the death
of patients. Several recent reports support a promigratory
and proinvasive role for RSK family proteins in cancer.40,41
Therefore, we sought to determine the contribution of
constitutively active RSK1 to cell migration and invasion in
the NM histologic subtype. We treated NM cells with
BI-D1870 and performed a Transwell cell migration assay.
After 6 hours, the migration of BI-D1870etreated WM 278
cells was reduced by 42.7% compared with that of DMSO-
treated cells (P < 0.001) (Figure 3A). Similarly, RSK
inhibition with BI-D1870 decreased the number of WMajp.amjpathol.org - The American Journal of Pathology
Figure 4 p90 ribosomal S6 kinase (RSK) inhi-
bition suppresses a promotile transcriptional pro-
gram. A: Heat map demonstrating down-regulation
of 200 mRNAs involved in cell motility and/or cell
adhesion after RSK inhibition. Yellow bars indicate
the basal mRNA expression level. Blue bars indicate
mRNA down-regulated 1.33 fold (P < 0.005)
compared with dimethyl sulfoxide (DMSO)etreated
cells. B: Venn diagram classifying 200 mRNAs that
were down-regulated after RSK inhibition and
functionally annotated with biological process
terms related to cell motility and/or cell adhesion.
C: Results from mRNA array demonstrating down-
regulated expression of matrix metalloproteinase
2 (MMP-2) and ﬁve other related transcripts after
24 or 48 hours of treatment with BI-D1870. Data
were normalized by setting DMSO-treated cells to
100%, and microarray was conﬁrmed using
quantitative RT-PCR (RT-qPCR). D: Human MMP
antibody array comparing four superﬁcial
spreading melanoma (SSM) and four nodular
melanoma (NM) metastatic samples. Boxes indi-
cated correspond to tissue inhibitor of metal-
loproteinases 1 (TIMP-1) and MMP-8 as indicated
in the key. E: Quantitative spot density analysis
of the array shown in D. The intensity of each
spot was normalized to the positive control, and
duplicate values were evaluated as a mean. F:
Validation of the array using immunohistochem-
ical analysis. NM metastatic tissue showed higher
expression of MMP-8 relative to SSM metastatic
tissue. Samples were scored based on intensity
(0 to 2) (mean of nine metastatic SSM samples
and 10 metastatic NM samples). Data are given as
means  SEM. *P < 0.05. Original magniﬁcation:
20 (F); 40 (insets, F).
RSK1 Hyperactivation in Nodular Melanoma3248 cells that traversed the migration chamber by 55.6%
compared with DMSO-treated cells (P < 0.001)
(Figure 3A).
In parallel experiments, we assessed whether RSK acti-
vation altered the invasive potential of NM by pretreating
WM 278 and WM 3248 VGP cells with 5 mmol/L BI-D1870
for 20 hours and measuring their invasion through an extra-
cellular matrix (Matrigel). WM 278 and WM 3248 cells that
had been pretreated with BI-D1870 demonstrated a 55.8%
and 57.3% reduction in cell invasion, respectively, compared
with vehicle-treated controls (P < 0.001) (Figure 3B).
Crucially, we conﬁrmed that the RSK1 isoform was critical
to melanoma cell invasion by performing an invasion assay
with WM 3248 cells in which RSK1 expression was
depleted after transfection with RSK1-speciﬁc siRNA and
observed a 77.8% reduction in cell invasion after RSK1
knockdown compared with nontargeting siRNA-transfectedThe American Journal of Pathology - ajp.amjpathol.orgcells (P < 0.0001) (Figure 3C). Taken together, these data
indicate that RSK1 may contribute to the invasive NM
phenotype by promoting cell migration and invasion.RSK1 Activation Orchestrates a Program of Gene
Expression that Promotes Cell Motility and Adhesion
and Differential Expression of MMP-8 and TIMP-1 in
NM-Derived Cell Lines and Tissues
To elucidate the mechanisms by which RSK inhibition mod-
ulates melanoma cell migration and invasion, we performed
unbiased mRNA array proﬁling using total mRNA isolated
from WM 278 and WM 3248 VGP cells that were treated in
duplicate with vehicle (DMSO) or 5 mmol/L BI-D1870 for 24
or 48 hours. To conﬁrm that BI-D1870 leads to decreased
p-RSK1 protein levels, we assessed the expression of p-RSK1711
Figure 5 Constitutive activation of protein S6 kinase, 90 kDa, polypeptide
1 (RSK1) accelerates melanoma tumor onset and invasion in zebraﬁsh. A:
Melanoma-free survival curve of miniCoopR-green ﬂuorescent protein (GFP)e,
miniCoopR-Myr-RSK1e, and miniCoopR-RSK-deltaCCTeinjected zebraﬁsh. B:
Histologic sections of zebraﬁsh RSK1dCCT- and Myr-RSK1eexpressing mela-
nomas were stained with hematoxylin and eosin to assess tumor invasion
depth. Arrows indicate muscular invasion by melanoma cells. C: Depth of
invasion was measured for each tumor and was quantiﬁed by averaging the
depth of invasion of four tumors for each group (RSK1dCCT and Myr-RSK1).
Data are given as means  SEM. ***P < 0.001 compared with dominant-
negative RSK1-expressing tumors.
Salhi et al(S380) in an NM-derived cell line (WM 278); we observed
that p-RSK1 expression was decreased by a factor of 2.4 (data
not shown).
We reasoned that RSK inhibitionwould repress expression of
genes implicated in invasion andmigration; thus, we focused on
analysis of those genes that were signiﬁcantly down-regulated
(P < 0.005) in both cell lines after treatment with BI-D1870 at
24 and 48 hours compared with the equivalent DMSO-treated
cells. This identiﬁed 1398 mRNA probes (Figure 4A and
Supplemental Table S3), for which the corresponding genes
were annotated using the National Institute of Allergy and In-
fectious Diseases/NIH Database for Annotation, Visualization,
and Integrated Discovery (DAVID) Bioinformatics Resource
6.7. Gene Ontology analysis of this data set revealed signiﬁcant
enrichment for Gene Ontology biological process terms related
to cell motility (enrichment score, 3.22; P < 0.001) and cell
adhesion (enrichment score, 2.37; PZ 0.0025). We conﬁrmed
these ﬁndings using the AmiGO database (http://amigo1.
geneontology.org/cgi-bin/amigo/go.cgi, last accessed October
23, 2014) focusing on 974 unique genes that correspond to the
1398 down-regulated mRNA probes; 66 genes belong to the
functional class cell motility (GO: 0048870), and 54 genes
belong to the functional class cell adhesion (GO: 2000145)
(Figure 4B). Twenty-one genes overlapped and belonged to
both functional sets and the BI-D1870 down-regulated gene set.
In the BI-D1870 down-regulated gene set, we noted enrichment
for several MMPs, which are known to be involved in the
digestion and turnover of the extracellular matrix42 and have
previously been implicated in melanoma invasion, including
MMP-2.43 Furthermore, there was a signiﬁcant concomitant
reduction (P< 0.005) in the expression of genes that are known
to induce MMP-2 expression/activation, including ATF1,
CCL2, CXCL1, TIMP3, and CXCL8 (IL-8), a ﬁnding that we
conﬁrmed in BI-D1870etreated WM 278 cells using quanti-
tative RT-PCR (Figure 4C).
To investigate the relevance of the decreased expression of
metalloproteinases after RSK inhibition, we used a commer-
cially available antibody array to compare the expression of
various MMPs and TIMPs between metastatic melanoma
samples from patients with primary SSM and primary NM
(nZ 4 for each subtype) (Figure 4D). Quantitative analysis of
the array spot densities when comparing metastatic samples
from SSM patients with metastatic samples from NM patients
revealed signiﬁcant increases in the protein levels of MMP-8
and TIMP-1 (P Z 0.03 and P Z 0.05, respectively) in
tissues that originated from the NM subtype (Figure 4E).
Because MMP-8 was the most strikingly overexpressed, we
performed immunohistochemical analysis using representa-
tive formalin-ﬁxed, parafﬁn-embedded metastatic samples
from SSM and NM patients (nZ 9 and nZ 10, respectively)
with an MMP-8especiﬁc antibody. These experiments
revealed considerably higher cytoplasmic staining (2.3-fold
increase) of MMP-8 in NM metastatic tissues compared with
the SSM tissues (Figure 4F). Consistent with this ﬁnding, we
observed a signiﬁcant decrease in MMP-8 expression in the
two NM cell lines on RSK1 inhibition in the mRNA array712analysis (P < 0.005; fold reduction of 4.85 and 4.95 in WM
278 and WM 3248, respectively) (Supplemental Table S3).
In addition, we performed an invasion assay on two NM cell
lines (WM 278 and WM 3248) that had been transfected with
siRNA againstMMP8 or TIMP1 or cotransfected with both.We
observed a slight decrease (14%) in the invasion of NM cells on
MMP-8 inhibition only compared with cells transfected with
scrambled siRNA (data not shown). However, when cells were
cotransfected with si-MMP-8 and si-TIMP-1, we observed a
signiﬁcant decrease in invasion of both NM cell lines (WM 278
andWM3248; amean 2.89-fold decrease;PZ 0.0005; data not
shown). These results suggest that the invasive phenotype of the
NM subtype might not rely on a single MMP but on a
concomitant and cooperative effect of several MMPs/TIMPs.
Together, these data suggest that RSK1 drives a transcriptional
program that promotes melanoma cell migration, invasion, and
adhesion and that RSK1 might promote MMP-mediated inva-
sion in NM, thus contributing to the distinctive biology of
metastasis in this histologic subset of melanoma.Constitutive RSK1 Activation Is Associated with
Increased Melanoma Progression and Invasion in
Zebraﬁsh
To conﬁrm the role of constitutive RSK1 activation in the
development and progression of melanoma in vivo, we used a
high-throughput zebraﬁsh model Tg[mitfa:BRAF(V600E),ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Proposed role of protein S6 kinase, 90 kDa, polypeptide 1
(RSK1) activation in a parallel progression model of melanoma. Schematic
depicting the linear progression model of melanoma and the parallel pro-
gression model that we propose. Linear progression model: Superﬁcial
spreading melanoma (SSM) and nodular melanoma (NM) grow according to
a linear model of progression, as malignant or normal melanocytes spread
radially and then invade vertically. Parallel progression model: SSM and NM
develop along divergent pathways from the transformed melanocyte to the
primary melanoma, and these differences are maintained as the tumors
invade and metastasize. p-RSK1, phospho-RSK1; RGP, radial growth phase;
VGP, vertical growth phase.
RSK1 Hyperactivation in Nodular Melanomap53M214K/M214K]24 in which we used miniCoopR, a tol2-
based transposon vector, to express a constitutively active,25
myristoylated human RSK1 speciﬁcally in melanocytes. In
this model system, cooperating genes can be tested for the
ability to accelerate or slow melanoma initiation. There is no
mouse model of NM or SSM that we could use as an alter-
native approach. As experimental controls, we also expressed
green ﬂuorescent protein or an inactive RSK1 mutant
(RSK1dCCT, generated by deletion of the last 11 amino
acids, which encode an ERK docking site and, thus, prevent
binding of ERK). We found that melanocyte-speciﬁc
expression of constitutively active RSK1 (Myr-RSK1)
signiﬁcantly accelerated melanoma onset compared with
green ﬂuorescent protein (PZ 2.92 1010) (Figure 5A) or
RSK1 mutant-expressing animals (P Z 1.81  107)
(Figure 5A). These data indicate that constitutively active
RSK1 can cooperate with oncogenic BRAF to accelerate
tumor onset in vivo.
To extend this ﬁnding, we analyzed tumor invasion
in vivo, comparing the depth of invasion between green
ﬂuorescent protein and Myr-RSK1 tumors. The depth of
invasion was measured on four tumors from each group
(Myr-RSK1e and RSK1dCCT-expressing tumors), and we
found that tumors expressing constitutively active RSK1
invaded signiﬁcantly deeper into muscle compared with
tumors expressing the dominant-negative form of RSK1
(Figure 5B) (an average of 0.11 mm for the RSK1dCCT-
expressing tumors versus 0.66 mm for Myr-
RSK1eexpressing tumors; P Z 0.0002) (Figure 5C). This
ﬁnding suggests that activated RSK1 may contribute to the
invasive phenotype observed in NM tumors.Discussion
Herein, we investigated the hypothesis that subtype-speciﬁc
differences between NM and SSM histologic subtypes persist
throughout the progression of primary melanoma to meta-
static disease and may account for the distinct biological
behavior of each subtype. We identiﬁed preferential activa-
tion of RSK1 in VGP cell lines and demonstrated constitutive
phosphorylation of RSK1 in VGP cell lines and metastatic
NM patient tissues, suggesting that RSK1 activation is
maintained throughout the progression of NM from primary
to metastatic disease. In addition, we provide in vitro and
in vivo evidence that supports a role for RSK1 activation in
promoting NM growth and invasion, suggesting that it plays
a driving role in the aggressive phenotype of this subtype.
A growing body of clinical, pathologic, and molecular data
supports the concept that primary NM and SSM evolve as
distinct biological entities.44 For example, we and others have
identiﬁed evidence supporting distinct pathways of develop-
ment from transformedmelanocytes to invasive SSM andNM,
such as the presence of recurrent SSM-speciﬁc deletions that
are not present in nevi or NM,17 distinct subtype-speciﬁc
miRNA and mRNA expression patterns between SSM andThe American Journal of Pathology - ajp.amjpathol.orgNM that were independent of thickness,15,16,18 and, more
recently, recurrent subtype-speciﬁc activating mutations in the
GTPase RAC1.45 These data argue against a model in which
SSM and NM develop along a linear pathway of progression
that begins with the transformation of epidermal melanocytes
and for which the difference between subtypes is limited to the
speed with which the transformed melanocytes invade the
dermis through a VGP (Figure 6).
We identify RSK1 activation as a feature of metastatic
melanoma derived from NM, where it is preferentially
maintained throughout the progression to metastasis. This
distinction between metastatic NM and metastatic SSM is
consistent with the study by Haqq et al,46 who compared
gene expression signatures at different stages of malignant
melanoma progression and identiﬁed two dichotomous gene
expression patterns in metastases, reﬂecting those seen in
VGP or RGP cells of primary melanoma. However, the
present analysis is unique given the comparison of the
expression and activation of signal transduction proteins
between melanoma subtypes rather than contrasting mRNA
expression proﬁles or copy number alterations. Together,
these ﬁndings suggest that the differences that arise between
primary melanoma subtypes persist throughout the invasive
and metastatic processes. In addition to explaining, in part,
the inherent biological differences between melanoma his-
tologic subtypes, a revised model of melanoma progression
may have implications for the subtype-speciﬁc treatment of
metastatic melanoma.713
Salhi et alWe prioritized studying activated RSK1 as a speciﬁc
feature of NM of the 18 signiﬁcantly different proteins
identiﬁed on the protein array for several reasons. First, we
reasoned that activated RSK1 might play a key role in
melanoma progression because it is situated in two signaling
pathways that are cumulatively dysregulated in >90% of
melanomas: the RAS-RAF-MEK-ERK and the PI3K/Akt
pathways.47e49 Second, RSK signaling has been shown to
facilitate signaling from activated BRAF to the mammalian
target of rapamycin in melanoma and to promote tumor
growth.30 We did not observe a correlation between acti-
vation of BRAF and RSK1 in NM cells, suggesting that
RSK1 hyperactivation in this subtype can also result from
BRAF-independent stimuli. In this regard, we did not ﬁnd
evidence to suggest that there are activating mutations in
RSK1 in melanoma when we analyzed data from The
Cancer Genome Atlas and our own RSK1 melanoma
sequencing (data not shown).
The present data support a role for RSK1 hyperactivation
in melanoma progression and a role for RSK1 in promoting
the migration and invasion of NM cells. First, treatment of
melanoma cells with BI-D1870, a small-molecule pan-RSK
inhibitor,50 caused a signiﬁcant reduction in melanoma cell
migration and invasion in vitro. We used BI-D1870 in cell
culture experiments at a ﬁnal concentration of 5 mmol/L,
which is half the concentration used in other published
studies.51 Second, the zebraﬁsh melanoma model indicated
that RSK1 activation signiﬁcantly accelerated melanoma
development and invasion in vivo. To our knowledge, there
is no genetic mouse model of SSM and NM. Third, BI-
D1870 treatment of melanoma cell lines was associated
with altered expression of genes associated with cell
motility and cell adhesion and, in particular, with reduced
levels of several MMPs, which, together with their tissue
inhibitors (TIMPs), have been implicated in tumor pro-
gression and metastasis.52,53
Comparing MMP and TIMP expression in metastatic
tissues from SSM and NM patients, we observed over-
expression of MMP-8 and TIMP-1 exclusively in tumors
derived from the NM subtype, suggesting that these proteins
may have a role in the pathogenesis of NM metastasis.
In the mRNA microarray we performed on NM cells on
RSK1 inhibition, we observed a signiﬁcant concordant
decrease in MMP-8 expression (4.85- and 4.95-fold
reductions in WM 278 and WM 3248 cells, respectively;
P < 0.005), and cotransfection of siRNA against MMP-8
and TIMP-1 produced a signiﬁcant reduction in the inva-
sive phenotype of NM cells. RSK1 has been shown to be
overexpressed in breast and prostate cancers28,29 and to
stimulate cell motility and invasion by activating a tran-
scriptional program that modulates the extracellular matrix,
the intracellular motility apparatus, and receptors that
mediate communication between these two compartments.54
Furthermore, a genome-wide RNA interference screen
demonstrated that multiple tumorigenic signaling pathways
converge on RSK to stimulate cell migration and invasion714and accelerate metastasis.41 Last, in vitro studies suggest
that novel inhibitors of RSK function may hold promise for
the treatment of a subset of cancers with RSK dependence.55
Further work is required to determine whether RSK inhi-
bition might be an effective therapeutic strategy for the
treatment of metastatic NM. A recent report showed that the
RSK isoforms RSK3 and RSK4 mediate resistance to PI3K
inhibitors in breast cancer,56 an interesting ﬁnding given
that combined MEK/ERK and PI3K pathway blockade
represents a promising approach to inhibit the growth of
metastatic melanoma with activating BRAF or NRAS
mutations.57,58
In summary, the present data indicate that RSK1 activation
is a feature of the NM subtype and that it contributes to the
invasion and progression of this disease. We demonstrate
persistent RSK1 activation in the metastases of NM patients,
suggesting that different subtypes of primary melanoma might
use distinct biological pathways to invade and metastasize, a
ﬁnding with implications for the development of subtype-
speciﬁc therapies for the treatment of metastatic melanoma.
This ﬁnding emphasizes the inherent biological variability of
primary and metastatic melanoma histologic subtypes.
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